High Dose Flupenthixol Decanoate in Chronic Schizophrenia

1979 ◽  
Vol 135 (2) ◽  
pp. 175-179 ◽  
Author(s):  
R. G. McCreadie ◽  
W. L. Flanagan ◽  
J. McKnight ◽  
A. Jorgensen
Keyword(s):  
Side Effects ◽  
Mental State ◽  
Standard Dose ◽  
Chronic Schizophrenia ◽  
Interindividual Variation ◽  
High Dose ◽  
Drug Resistant ◽  
Extrapyramidal Side Effects ◽  
Double Blind ◽  
Flupenthixol Decanoate

SummaryIn a double-blind trial, female ‘drug-resistant’ chronic schizophrenic in-patients were given high dose or standard dose flupenthixol decanoate for 13 weeks. Plasma flupenthixol levels showed a five-fold interindividual variation, but were consistently higher with the high dose. Analysis of final scores showed no statistically significant differences between groups with regards to mental state, ward behaviour and extrapyramidal side-effects. When compared with pre-trial scores, the extrapyramidal side-effects worsened significantly in the high dose patients and social withdrawal decreased in the standard dose patients. The mental state of a sub-group of patients, possibly drug resistant for pharmacokinetic reasons, improved significantly on the high dose over the 13 weeks.

High Dosage Haloperidol in Chronic Schizophrenia

1977 ◽  
Vol 131 (3) ◽  
pp. 310-316 ◽  
Author(s):  
Robin G. McCreadie ◽  
Ian M. MacDonald
Keyword(s):  
Alkaline Phosphatase ◽  
Side Effects ◽  
Serum Alkaline Phosphatase ◽  
Controlled Trial ◽  
Chronic Schizophrenia ◽  
Drug Resistant ◽  
Extrapyramidal Side Effects ◽  
Double Blind ◽  
High Doses

In a double blind chlorpromazine-controlled trial, high dosage haloperidol (100 mg daily) given for three months, appreciably improved the mental state of male chronic ‘drug resistant’ schizophrenic in-patients in the rehabilitation/long-stay unit of one psychiatric hospital. The results of a three-month follow-up suggested that the improvement could be maintained in some patients on lower doses of the drug.Serious extrapyramidal side effects were not seen at high doses. However, the majority of patients on haloperidol showed a deterioration in ward behaviour, possibly related to drowsiness, and developed raised serum alkaline phosphatase levels. These side effects disappeared in the follow-up period when either the drug was discontinued or the dose of haloperidol reduced.

scholarly journals High-Dose Adrenaline in Adult In-Hospital Asystolic Cardiopulmonary Resuscitation: A Double-Blind Randomised Trial

1993 ◽  
Vol 21 (2) ◽  
pp. 192-196 ◽  
Author(s):  
J. Lipman ◽  
W. Wilson ◽  
S. Kobilski ◽  
J. Scribante ◽  
C. Lee ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Cardiac Arrest ◽  
Intensive Care ◽  
Side Effects ◽  
Cardiopulmonary Resuscitation ◽  
Standard Dose ◽  
Randomised Trial ◽  
High Dose ◽  
Double Blind ◽  
To Receive

Forty intensive care unit patients requiring cardiopulmonary resuscitation were randomised to receive either the standard dose of adrenaline (1 mg every five minutes) or high-dose adrenaline (10 mg every five minutes). In the majority of patients, overwhelming sepsis was the major contributing factor leading to cardiac arrest. In this group of patients no difference could be detected in response to high-dose adrenaline compared with the standard dose. Although no side-effects were noted with this high dose of adrenaline, more investigation is required prior to its routine use in cardiopulmonary resuscitation.

Depressive and Extrapyramidal Symptoms and Clinical Effects: A Trial of Fluphenazine versus Flupenthixol in Maintenance of Schizophrenic Out-patients

1979 ◽  
Vol 135 (6) ◽  
pp. 515-523 ◽  
Author(s):  
Angela Knights ◽  
M. S. Okasha ◽  
Mohamed Ali Salih ◽  
S. R. Hirsch
Keyword(s):  
Depressive Symptoms ◽  
Side Effects ◽  
Clinical Data ◽  
Clinical Effects ◽  
Extrapyramidal Side Effects ◽  
Double Blind Trial ◽  
Double Blind ◽  
Fluphenazine Decanoate ◽  
Flupenthixol Decanoate

SummaryFifty-seven patients with a diagnosis of schizophrenia were started on either fluphenazine decanoate or flupenthixol decanoate injections in a double-blind trial just prior to discharge into the community. During the six month follow-up 30 per cent dropped out of the treatment. Of those observed for six months, 7 per cent relapsed, 54 per cent experienced depressive symptoms and 88 per cent extrapyramidal side-effects. Analysis of both clinical data and the ratings failed to discriminate between the two drugs.

Haloperidol: New Addition to the Drug Treatment of Schizophrenia

1967 ◽  
Vol 12 (6) ◽  
pp. 597-602 ◽  
Author(s):  
H. G. Lafave ◽  
Alex Stewart ◽  
G. Segovia
Keyword(s):  
Side Effects ◽  
Laboratory Tests ◽  
Epileptic Seizures ◽  
Chronic Schizophrenia ◽  
Extrapyramidal Side Effects ◽  
Double Blind ◽  
Long Duration ◽  
Drug Free ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

A double-blind crossover study was conducted to compare the effects of haloperidol with those of trifluoperazine in patients with Chronic schizophrenia of long duration. Both medications were administered to the patients following a drug-free and placebo period, initially and at the crossover. Tests of mental status were used to indicate changes produced by drag administration and included the BPRS, IMPS, MACC and the Rockland-Pollin scales. Results of the study indicate that the drugs both had a similar therapeutic effect and that the effect tended to be similar. Extrapyramidal side effects were observed in patients who received either haloperidol or trifluoperazine. One patient receiving haloperidol experienced epileptic seizures during the course of treatment. No significant abnormalities or trends toward such were seen in the battery of laboratory tests performed on each patient.

Nebulized Albuterol in Acute Childhood Asthma: Comparison of Two Doses

PEDIATRICS ◽  
1990 ◽  
Vol 86 (4) ◽  
pp. 509-513
Author(s):  
Suzanne Schuh ◽  
Michael J. Reider ◽  
Gerald Canny ◽  
Emily Pender ◽  
Thomas Forbes ◽  
...  
Keyword(s):  
Side Effects ◽  
Pediatric Patients ◽  
Serum Potassium Level ◽  
Acute Asthma ◽  
Standard Dose ◽  
Forced Expiratory Volume ◽  
High Dose ◽  
Double Blind Study ◽  
Double Blind ◽  
Severe Acute Asthma

Thirty-three children and adolescents from 5 to 17 years of age with moderate to severe acute asthma were given nebulized albuterol therapy in either a high (0.30 mg/kg body weight) or standard (0.15 mg/kg) dose administered at three hourly intervals in a randomized double-blind study. The high-dose hourly regimen resulted in significantly greater improvement in the forced expiratory volume in 1 second (FEV1). Furthermore, patients receiving the high dose showed a steady improvement in the FEV1 from the start to the end of the study, whereas FEV1 plateaued after the second dose in the standard-dose group. Although a rise in heart rate and a fall in serum potassium level occurred, neither of these changes nor other side effects were different in the two groups. The high-dose therapy resulted in much higher serum albuterol levels than the standard dose. There was no correlation between the drug levels and side effects or initial and subsequent FEV1. It is concluded that occasional hourly high-dose albuterol therapy should be considered for some pediatric patients with acute asthma of moderate severity, especially those who relapse between doses.

scholarly journals Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis

2018 ◽  
Vol 62 (12) ◽  
Author(s):  
S. Dian ◽  
V. Yunivita ◽  
A. R. Ganiem ◽  
T. Pramaesya ◽  
L. Chaidir ◽  
...  
Keyword(s):  
Adverse Events ◽  
Phase Ii ◽  
Tuberculous Meningitis ◽  
Standard Dose ◽  
Geometric Mean ◽  
Phase Iii ◽  
High Dose ◽  
Treatment Area ◽  
Double Blind ◽  
Time Curve

ABSTRACT High doses of rifampin may help patients with tuberculous meningitis (TBM) to survive. Pharmacokinetic pharmacodynamic evaluations suggested that rifampin doses higher than 13 mg/kg given intravenously or 20 mg/kg given orally (as previously studied) are warranted to maximize treatment response. In a double-blind, randomized, placebo-controlled phase II trial, we assigned 60 adult TBM patients in Bandung, Indonesia, to standard 450 mg, 900 mg, or 1,350 mg (10, 20, and 30 mg/kg) oral rifampin combined with other TB drugs for 30 days. The endpoints included pharmacokinetic measures, adverse events, and survival. A double and triple dose of oral rifampin led to 3- and 5-fold higher geometric mean total exposures in plasma in the critical early days (2 ± 1) of treatment (area under the concentration-time curve from 0 to 24 h [AUC0–24], 53.5 mg · h/liter versus 170.6 mg · h/liter and 293.5 mg · h/liter, respectively; P < 0.001), with proportional increases in cerebrospinal fluid (CSF) concentrations and without an increase in the incidence of grade 3 or 4 adverse events. The 6-month mortality was 7/20 (35%), 9/20 (45%), and 3/20 (15%) in the 10-, 20-, and 30-mg/kg groups, respectively (P = 0.12). A tripling of the standard dose caused a large increase in rifampin exposure in plasma and CSF and was safe. The survival benefit with this dose should now be evaluated in a larger phase III clinical trial. (This study has been registered at ClinicalTrials.gov under identifier NCT02169882.)

Zetidoline, A New Antipsychotic

1984 ◽  
Vol 145 (3) ◽  
pp. 294-299 ◽  
Author(s):  
T. Silverstone ◽  
S. Levine ◽  
H. L. Freeman ◽  
A. Dubini
Keyword(s):  
Side Effects ◽  
Dopamine Receptor ◽  
Blind Study ◽  
Double Blind Study ◽  
Extrapyramidal Side Effects ◽  
Double Blind ◽  
Receptor Blocking ◽  
Selective Dopamine

SummaryZetidoline (ZTD), a compound chemically unrelated to any available antipsychotic, with selective dopamine receptor-blocking properties, was compared with haloperidol (HLP) in a double-blind study on 56 in-patients who had either first episodes or acute relapses of schizophrenia. ZTD was found to be safe, as effective as HLP, and to produce significantly fewer extrapyramidal side-effects (EPS).

scholarly journals Check the effects: systematic assessment of antipsychotic side-effects in an inpatient cohort

2020 ◽  
Vol 10 ◽  
pp. 204512532095711
Author(s):  
Caroline Hynes ◽  
Stephen McWilliams ◽  
Mark Clarke ◽  
Ita Fitzgerald ◽  
Larkin Feeney ◽  
...  
Keyword(s):  
Side Effects ◽  
Rating Scales ◽  
Rating Scale ◽  
Standard Dose ◽  
Well Being ◽  
High Dose ◽  
Negative Consequences ◽  
Adherence Assessment ◽  
Dose Combination ◽  
Antipsychotic Side Effects

Background: Antipsychotics are associated with a range of side-effects that can influence patients’ subjective well-being negatively resulting in poor adherence. In order to limit the negative consequences of side-effects, they should be regularly systematically assessed. The aim of this study was to systematically assess antipsychotic side-effects in an inpatient cohort using validated rating scales. Methods: Eligible individuals prescribed an antipsychotic for at least 2 weeks were invited to have their side-effects assessed systematically. Results: A total of 208 individuals were assessed systematically for antipsychotic side-effects; 71.5% ( n = 138) stated that they had not reported side-effects to their clinician prior to the assessment. The most commonly reported side-effects were daytime drowsiness (75%), dry mouth (58.2%) and weight gain (50.0%), while the most distressing side-effects reported were erectile dysfunction (35.0%), sexual dysfunction (26.3%) and amenorrhoea (26.3%). There was no evidence of an association between side-effect severity/number of side-effects reported/distress caused by those taking high dose/combination antipsychotics versus standard dose monotherapy. Conclusion: Side-effects must be regularly and systematically assessed using a validated rating scale. As distress caused by side-effects plays a major role in non-adherence, assessment should examine distress and data on distressing side-effects should be available to those choosing an antipsychotic. Given the lack of correlation between high dose/combination antipsychotics and side-effects, treatment should be tailored to the individual based on response/tolerance and dose reduction/avoidance of polypharmacy should not be recommended to minimise side-effects.

Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial

2020 ◽  
Vol 2 (1) ◽  
pp. e14-e23 ◽  
Author(s):  
Inés Colmegna ◽  
Mariana L Useche ◽  
Katherine Rodriguez ◽  
Deirdre McCormack ◽  
Giuliana Alfonso ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Influenza Vaccine ◽  
Standard Dose ◽  
High Dose ◽  
Double Blind ◽  
Active Comparator ◽  
Comparator Trial
Sign in / Sign up

Export Citation Format

Share Document